Introduction.
concerning disease associated with considerable morbidity and mortality.(1) Bacterial causes 25 of IE and bacteremia have changed over the past few decades and now streptococci, 26 staphylococci, and enterococci have emerged as the major pathogens.(2) Among these, 27
Enterococcus has become the most challenging to treat. Barriers in treating these infections 28 include the need for multiple agents to demonstrate bactericidal activity and microbiological 29 cure (1); biofilm production among these bacteria (3, 4); and resistance to the mainstays of 30 therapy (i.e., ampicillin, penicillin, and vancomycin) (5). Biofilm production in enterococci is 31 common in E. faecalis, with worldwide rates reported between 26-100%, and 93% reported 32 in the US.(3) The 2005 American Heart Association recommendations for drug-resistant 33 -4 -We therefore evaluated the in vitro activity of daptomycin and linezolid alone and in 48 combination with gentamicin or rifampin against enterococci in an in vitro model with 49 sequestered high inoculum stationary phase infection using simulated endocardial 50 vegetations (SEV). (20, 22, 23) We also tested these regimens in an in vivo survival assay 51
using Galleria mellonella larvae. We used a vancomycin-susceptible biofilm-producing E. 52 faecalis and a vancomycin-resistant E. faecium. We also evaluated biofilm production of 53 these isolates. 
IE guidelines recommend > 8 weeks of linezolid or quinupristin/dalfopristin monotherapy for 283 the treatment of Native or Prosthetic Valve Enterococcal Endocarditis Caused by Strains 284
Resistant to Penicillin, Aminoglycoside, and Vancomycin.(1) In many cases these 285 treatments are not ideal; linezolid has inherent bacteriostatic activity (6, 44) was lower than desired due to limits on available pharmaceutical concentrations. It is 357 possible that the differences seen would not be significant if a higher concentration were 358 used. While G. mellonella received doses targeting the free peak concentration achieved in 359 humans, each drug was dosed only once, with survival being measured over 9 days, and 360 pharmacokinetic information including metabolism and excretion are unknown. 361
The results support daptomycin 6 or 10mg/kg, with gentamicin added for 24 hours, 362 against enterococci in simulated endocardial vegetations. Nonetheless, our results should be 363 applied to clinical practice with caution. Confirmation of these results in clinical studies is 364 needed before these regimens can be adopted for use in the care of patients. 
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Time ( Rifampin 300mg 2.6 2.50 Table 4 . Targeted vs. administered peak concentrations in G. mellonella models. a Linezolid concentrations were lower than targeted due to limits on the available pharmaceutical concentrations.
